**Supplementary Table S4: Patient characteristics according to *PTEN* mutational status**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Characteristic |  | Wild-type *PTEN*n = 31 | (%) | Mutant *PTEN*/phosphatasedomainn = 8 | (%) | Mutant *PTEN*/C2 domainn = 6 | (%) |
| **Age** | median (range) | 66 | (30-84) | 66 | (41-79) | 69 | (37-82) |
|  | ≥ 65 | 16 | (51.6) | 4 | (50.0) | 4 | (66.7) |
| **Sex** | Male | 18 | (58.1) | 3 | (37.5) | 3 | (50.0) |
|  | Female | 13 | (41.9) | 5 | (62.5) | 3 | (50.0) |
| **ECOG PS** | 0 | 15 | (48.4) | 6 | (75.0) | 3 | (50.0) |
|  | 1 | 16 | (51.6) | 2 | (25.0) | 3 | (50.0) |
| **Previous treatment****regimens** | 1 | 12 | (38.7) | 2 | (25.0) | 4 | (66.7) |
|  | ≥ 2 | 19 | (61.3) | 6 | (75.0) | 2 | (33.3) |
| **Primary cancer** | Gastric | 14 | (45.2) | 1 | (12.5) | 3 | (50.0) |
|  | Colorectal | 11 | (35.5) | 3 | (37.5) | 3 | (50.0) |
|  | Cholangiocarcinoma | 5 | (16.1) | 0 | (0.0) | 0 | (0.0) |
|  | Small intestine | 0 | (0.0) | 2 | (25.0) | 0 | (0.0) |
|  | Pancreatic | 0 | (0.0) | 2 | (25.0) | 0 | (0.0) |
|  | Duodenal | 1 | (3.2) | 0 | (0.0) | 0 | (0.0) |
| **Site of metastasis** | Liver | 6 | (19.4) | 3 | (37.5) | 0 | (0.0) |
|  | Lung | 4 | (12.9) | 2 | (25.0) | 1 | (16.7) |
|  | Lymph node | 25 | (80.6) | 6 | (75.0) | 4 | (66.7) |
|  | Peritoneum | 15 | (48.4) | 3 | (37.5) | 2 | (33.3) |
| **Number of****metastatic organs** | 1 | 14 | (45.2) | 5 | (62.5) | 4 | (66.7) |
|  | ≥ 2 | 17 | (54.8) | 3 | (37.5) | 2 | (33.3) |
| **TMB****(muts/Mb)** | median (range) | 33.2 | (3.6-83.6) | 43.2 | (36.9-85.3) | 46.7 | (29.9-93.0) |

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; TMB, tumor mutational burden